HEOR

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

Pharmacist shelving medicine in pharmacy

NHS could pay more for medicines under new plan

Changes to the threshold used by NICE to measure cost-effectiveness could be on the way as part of a plan that would raise NHS spending on medicines.

News

NICE finalises support for CSL's HAE therapy Andembry

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

Homeless man on ground beside subway entrance

PHTI delivers its verdict on DHTs for opioid use disorder

Digital health tech for opioid use disorder can be as effective as regular care, but it doesn't expand access and may increase the cost of care.

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ICER says US new drug launch prices have risen sharply

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

NHS could pay more for medicines under new plan

NICE finalises support for CSL's HAE therapy Andembry

PHTI delivers its verdict on DHTs for opioid use disorder

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

HEOR

Editor's Picks